LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) from a neutral rating to a buy rating in a report released on Monday, MarketBeat Ratings reports. LADENBURG THALM/SH SH currently has $16.00 price target on the stock.
A number of other research analysts also recently weighed in on the company. HC Wainwright reissued a buy rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a report on Tuesday, August 13th. Piper Sandler Companies reissued a buy rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a report on Friday, September 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average price target of $23.86.
Check Out Our Latest Stock Analysis on ACRV
Acrivon Therapeutics Price Performance
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. As a group, sell-side analysts expect that Acrivon Therapeutics will post -2.4 EPS for the current fiscal year.
Institutional Trading of Acrivon Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. increased its stake in shares of Acrivon Therapeutics by 39.2% in the first quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after purchasing an additional 1,695 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Acrivon Therapeutics by 6.6% in the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock worth $3,626,000 after purchasing an additional 31,208 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Acrivon Therapeutics in the first quarter worth $378,000. Dimensional Fund Advisors LP purchased a new stake in shares of Acrivon Therapeutics in the second quarter worth $58,000. Finally, XTX Topco Ltd purchased a new position in Acrivon Therapeutics during the second quarter valued at $61,000. 71.62% of the stock is owned by hedge funds and other institutional investors.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
See Also
- Five stocks we like better than Acrivon Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The 3 Best Retail Stocks to Shop for in August
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Most Effectively Use the MarketBeat Earnings Screener
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.